Albuterol enantiomer levels, lung function and QTc interval in patients with acute severe asthma and COPD in the emergency department

International Journal of Emergency Medicine

Volumn 4, Issue 1, 2011, Pages

  Yee, Kwang Choon ^a   Jacobson, Glenn A ^a   Wood Baker, Richard ^b   Walters, E Haydn ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; POTASSIUM; SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROCARDIOGRAPHY; EMERGENCY WARD; ENANTIOMER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; LUNG FUNCTION; MALE; MASS SPECTROMETRY; MEDICAL RECORD REVIEW; NEBULIZATION; OBSERVATIONAL STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE;

EID: 84857668232     PISSN: 18651372     EISSN: 18651380     Source Type: Journal    
DOI: 10.1186/1865-1380-4-30     Document Type: Article

References (40)

1. Renzoni E, Robinson S, Poole P, Ram FS: Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002, , 4: CD001495.
2. Emerman CL, Cydulka RK: Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1997, 29(4):474-8. (Pubitemid 27149198)
3. Nair S, Thomas E, Pearson SB, Henry MT: A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest 2005, 128(1):48-54. (Pubitemid 40994453)
4. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebocontrolled cross-over trial. Lancet 2004, 364(9444):1505-12. (Pubitemid 39410416)
5. Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Town GI, Taylor DR: Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J 1999, 14(2):283-7. (Pubitemid 29461290)
6. Walters EH, Walters J: Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment. Cochrane Database Syst Rev 2000, , 4: CD001285.
7. Bakale RP, Wald SA, Butler HT, Gao Y, Hong Y, Nie X, Zepp CM: Albuterol. A pharmaceutical chemistry review of R-, S-, and RS-albuterol. Clin Rev Allergy Immunol 1996, 14(1):7-35. (Pubitemid 126442500)
8. Schmekel B, Rydberg I, Norlander B, Sjosward KN, Ahlner J, Andersson RG: Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J 1999, 13(6):1230-5. (Pubitemid 29357136)
9. Lipworth BJ, Clark DJ, Koch P, Arbeeny C: Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997, 52(10):849-52. (Pubitemid 27473925)
10. Boulton DW, Fawcett JP: The pharmacokinetics of levoalbuterol: what are the clinical implications? Clin Pharmacokinet 2001, 40(1):23-40. (Pubitemid 32182112)
11. Agrawal DK, Ariyarathna K, Kelbe PW: (S)-Albuterol activates proconstrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004, 113(3):503-10. (Pubitemid 38338957)
12. Ameredes BT, Calhoun WJ: Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle. J Allergy Clin Immunol 2005, 116(1):65-72. (Pubitemid 40909750)
13. Hoshiko K, Morley J: Exacerbation of airway hyperreactivity by () salbutamol in sensitized guinea pig. Jpn J Pharmacol 1993, 63(2):159-63. (Pubitemid 23337278)
14. Johansson F, Rydberg I, Aberg G, Andersson RG: Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996, 14(1):57-64. (Pubitemid 126442503)
15. Boulton DW, Fawcett JP: Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin Pharmacol Ther 1997, 62(2):138-44. (Pubitemid 27373461)
16. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, Rollins TE, Rubin PD: Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998, 102(6 Pt 1):943-52. (Pubitemid 29018311)
17. Pleskow WW, Nelson HS, Schaefer K, Claus R, Roach JM: Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004, 25(6):429-36. (Pubitemid 40221591)
18. Truitt T, Witko J, Halpern M: Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003, 123(1):128-35. (Pubitemid 36126724)
19. Barnes PJ: Treatment with (R)-albuterol has no advantage over racemic albuterol. Am J Respir Crit Care Med 2006, 174(9):969-72, discussion 972-4.
20. O'Riordan TG, Mao W, Palmer LB, Chen JJ: Assessing the effects of racemic and single-enantiomer albuterol on airway secretions in long-term intubated patients. Chest 2006, 129(1):124-32. (Pubitemid 43265252)
21. Westerhof FJ, Zuidhof AB, Kok L, Meurs H, Zaagsma J: Effects of salbutamol and enantiomers on allergen-induced asthmatic reactions and airway hyperreactivity. Eur Respir J 2005, 25(5):864-72. (Pubitemid 40667685)
22. Ahrens R, Weinberger M: Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001, 108(5):681-4. (Pubitemid 33096194)
23. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ: Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 1999, 12(6):353-62. (Pubitemid 30015807)
24. Lotvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J: The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001, 108(5):726-31. (Pubitemid 33096202)
25. Abramson MJ, Bailey MJ, Couper FJ, Driver JS, Drummer OH, Forbes AB, McNeil JJ, Haydn Walters E: Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med 2001, 163(1):12-8. (Pubitemid 32095246)
26. Handley DA, Tinkelman D, Noonan M, Rollins TE, Snider ME, Caron J: Doseresponse evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000, 37(4):319-27. (Pubitemid 30418733)
27. Salpeter SR, Ormiston TM, Salpeter EE: Cardiovascular effects of betaagonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125(6):2309-21. (Pubitemid 38796452)
28. Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, Vardas PE: Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 2005, 127(6):2057-63.
29. Cazzola M, Matera MG, Donner CF: Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005, 65(12):1595-610. (Pubitemid 41138983)
30. Jacobson GA, Chong FV, Wood-Baker R: (R, S)-salbutamol plasma concentrations in severe asthma. J Clin Pharm Ther 2003, 28(3):235-8. (Pubitemid 36783100)
31. Australia N.A.C: Asthma management handbook 2006. South Melbourne, Australia: National Asthma Council Australia Ltd;, Sixth 2006.
32. Bell HM, McElnay JC, Hughes CM: Changing profile in the use of antiasthma drugs. Pharmacoepidemiol Drug Saf 1999, 8(6):385-94. (Pubitemid 29527860)
33. Rodrigo G, Rodrigo C: Early prediction of poor response in acute asthma patients in the emergency department. Chest 1998, 114(4):1016-21. (Pubitemid 28495895)
34. Jacobson GA, Chong FV, Davies NW: LC-MS method for the determination of albuterol enantiomers in human plasma using manual solid-phase extraction and a non-deuterated internal standard. J Pharm Biomed Anal 2003, 31(6):1237-43. (Pubitemid 36349741)
35. Ward JK, Dow J, Dallow N, Eynott P, Milleri S, Ventresca GP: Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man- no evidence of enantioselective lung metabolism. Br J Clin Pharmacol 2000, 49(1):15-22. (Pubitemid 30050482)
36. Rosenkranz B, Rouzier R, Kruse M, Dobson C, Ayre G, Horowitz A, Fitoussi S: Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Respir Med 2006, 100(4):666-72. (Pubitemid 43285754)
37. Hussein R, Charles BG, Morris RG, Rasiah RL: Population pharmacokinetics of perhexiline from very sparse, routine monitoring data. Ther Drug Monit 2001, 23(6):636-43. (Pubitemid 33086491)
38. Devadason SG: Recent advances in aerosol therapy for children with asthma. J Aerosol Med 2006, 19(1):61-6.
39. Melani AS: Inhalatory therapy training: a priority challenge for the physician. Acta Biomed 2007, 78(3):233-45. (Pubitemid 351599006)
40. Virchow JC: Guidelines versus clinical practice-which therapy and which device? Respir Med 2004, 98(Suppl B):S28-34. (Pubitemid 40029140)